Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

FDA approves Hikma Pharmaceuticals' generic version of Victoza, a once-daily GLP-1 injection for Type 2 diabetes. Other drugmakers also entering the market.

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...